ClinicalTrials.gg
RecruitingNCT07135427IgG in AATDUpdated Oct 27, 2026

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

A Phase 4 interventional study of 20-valent pneumococcal conjugate vaccine in Alpha 1-Antitrypsin, COPD and Antibody Deficiency, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Alabama at Birmingham · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 27, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Planned enrollment
28th of 55
30 · median 30
Started
2025
with 3 others
Phase 4
4 of 81
1 open now
Primary completion
2027-03
later than 3 of 20 live
Registered
78th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 28th largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 3 of the 20 other live ones, and was the 78th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.

To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

03

Conditions studied

  • Alpha 1-Antitrypsin
  • COPD
  • Antibody Deficiency
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults who are heterozygous for a SERPINA1 Z allele
  • Have either had no exacerbations or 2 or more exacerbations in the previous year
  • Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past

Exclusion criteria

Exclusion Criteria:

  • Received a pneumococcal conjugate vaccine within the past 5 years
  • Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SERPINA1 'Z' heterozygotes

    Participants who are heterozygous for the SERPINA1 'Z' allele with either 0 or 2+ exacerbations in the previous year, and have not received pneumococcal vaccination within 5 years will be given PCV20.

    Biological: 20-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Antibody response

    Pneumococcal antibody levels/function, total IgG levels, IgG subclass levels; magnitude of change from baseline

    Time frame: 4 weeks from baseline measurement

Secondary outcomes

  1. Lymphocyte profile

    B and T cell lymphocyte subsets

    Time frame: Baseline, 4 weeks post-vaccination

Other outcomes

  1. Gene variants

    Variants in SERPINA1, IGHG genes

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Sep 2027, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027was Jun 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 2027→Sep 2027
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Alabama at Birmingham · Birmingham, United StatesContact d•••@uabmc.edu · •••3411→d•••@uabmc.edu · •••3411
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Study completion Jun 2027→Sep 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Alabama at Birmingham · Birmingham, United StatesContact d•••@uabmc.edu · •••3411→d•••@uabmc.edu · •••3411
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135427
Collaborators
Alpha-1 Foundation
Responsible party
David Lafon (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 22, 2025
Start date
Sep 3, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

David LaFon, MD
Contact
dlafon@uabmc.edu
2059343411

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion